Articles

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Division of Cancer, Imperial College London
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust
Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust;MRC/EPSRC Newcastle Molecular Pathology Node, Newcastle upon Tyne
Division of Cancer, Imperial College London
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne;Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust;MRC/EPSRC Newcastle Molecular Pathology Node, Newcastle upon Tyne
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne;Department of Pediatric and Adolescent Hematology and Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust
AstraZeneca, Cambridge, UK
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
Vol. 102 No. 7 (2017): July, 2017 https://doi.org/10.3324/haematol.2016.163030